Conemaugh Diabetes Institute receives grant
The Conemaugh Diabetes Institute was awarded a grant from the National Council on Health, Physical Activity and Disability to increase inclusivity awareness and recruitment for the National Diabetes Prevention Program.
According to the Centers for Disease Control and Prevention, 25 percent of the adults in Pennsylvania have a disability and 43 percent have obesity and are at risk for diabetes.
The grant will help to identify and provide support to people with disabilities who are at high risk for diabetes.
Conemaugh Health offering antibody therapy
Conemaugh Health System is offering casirivimab and imdevimab monoclonal antibody therapy for treatment of non-hospitalized patients with a mild or moderate case of COVID-19.
Developed by pharmaceutical company Regeneron Pharmaceuticals Inc., the drug received emergency use authorization from the Food and Drug Administration.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses.
Patients receiving treatment at Conemaugh Memorial Medical Center will be required to stay for a duration of up to two hours.
Carbon storage online panel discussion planned
Carbon storage and what it means for Pennsylvania’s forested land will be the theme of an online panel discussion at noon Oct. 12. The free event is sponsored by the State College and Susquehanna Valley chapters of Citizens’ Climate Lobby.
Topics include how trees store carbon and why that matters, how carbon markets can generate income for small forest landowners and the importance of a robust wood products market in preserving forested land.
While there is no charge to attend this online event, registration is required. Those interested may register at https://exploringforestcarbon.eventbrite.com.